India Glycols Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company delivered a robust performance, reporting annual consolidated revenue of ₹9,826.63 crore and a net profit after tax of ₹292.76 crore. The Board of Directors also highlighted significant progress regarding its ongoing corporate restructuring, specifically the demerger of the Bio Pharma and Spirits & Biofuel undertakings.
Financial Performance Highlights
For the financial year ended March 31, 2026, India Glycols reported a strong growth trajectory. The company achieved a consolidated annual revenue of ₹9,826.63 crore, compared to ₹9,038.95 crore in the previous year. The consolidated net profit for the year stood at ₹292.76 crore, reflecting a healthy increase from the ₹230.92 crore recorded in the prior year. For the final quarter (Q4) ended March 31, 2026, the company recorded a revenue of ₹2,360.01 crore.
Segment-Wise Overview
The company continues to diversify its operations across several key sectors. Potable Spirits remains the largest contributor to revenue, accounting for ₹6,946.43 crore in the fiscal year. Other key segments include Bio-based Specialities and Performance Chemicals, which contributed ₹1,202.50 crore, and the Bio-Fuel segment, which saw significant growth, generating ₹1,469.93 crore. The Ennature Biopharma segment also contributed ₹207.77 crore to the total annual revenue.
Strategic Corporate Updates
The company is currently executing a Composite Scheme of Arrangement focused on the demerger of its Bio Pharma and Spirits & Biofuel undertakings. This strategic initiative aims to create independent, focused entities for these business segments. The scheme has already received necessary approvals from shareholders and the NCLT, with an appointed date of April 1, 2026. The company maintains that these restructuring efforts will unlock value for all stakeholders without adversely impacting its existing financial operations.
Dividend Declaration
Demonstrating its commitment to rewarding shareholders, the Board of Directors approved an interim dividend of ₹7.50 per equity share (face value of ₹5 each) for the financial year 2025-26, as confirmed during the board meeting held on March 17, 2026.
Source: BSE
